Pages that link to "Q28210453"

The following pages link to The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains (Q28210453):

Displaying 27 items.

• Hematopoietic cell kinase (Hck) isoforms and phagocyte duties - from signaling and actin reorganization to migration and phagocytosis (Q24319772) (← links)
• Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors (Q26849792) (← links)
• Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (Q27025242) (← links)
• (Q28177355) (redirect page) (← links)
• Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells (Q28512494) (← links)
• Emerging drugs for chronic myeloid leukemia (Q33536762) (← links)
• Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase (Q33988398) (← links)
• Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia (Q34016866) (← links)
• Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents (Q34787546) (← links)
• Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells (Q35751017) (← links)
• Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells (Q36508969) (← links)
• Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib (Q36677456) (← links)
• Flying under the radar: the new wave of BCR-ABL inhibitors (Q36939898) (← links)
• The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias (Q36967858) (← links)
• Targeted therapy of chronic myeloid leukemia (Q37752572) (← links)
• Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia (Q37811878) (← links)
• The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose (Q37896606) (← links)
• Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation. (Q39531618) (← links)
• The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation. (Q40235633) (← links)
• The challenge of developing robust drugs to overcome resistance (Q43221173) (← links)
• Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia (Q44851706) (← links)
• Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells (Q45133282) (← links)
• Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro (Q46060618) (← links)
• G-protein coupled receptor 34 activates Erk and phosphatidylinositol 3-kinase/Akt pathways and functions as alternative pathway to mediate p185Bcr-Abl-induced transformation and leukemogenesis. (Q53007093) (← links)
• BCR-ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph+ ALL. (Q55346179) (← links)
• Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors (Q79529732) (← links)
• Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia (Q79897814) (← links)